Lexicon Pharmaceuticals | LXRX - 負債





負債 変化する 日付
Abbott USD 13.86B 919M 2025-12
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
BioMarin Pharmaceutical USD 605.86M 1.62M 2025-12
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.5B 3.6M 2025-12
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Illumina USD 2.55B 23M 2025-12
Insmed USD 727.89M 163.33M 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 47.93B 2.14B 2025-12
Lexicon Pharmaceuticals USD 99.51M 243K 2023-12
MacroGenics USD 37.01M 238K 2025-09
MannKind USD 119.91M 73.09M 2025-09
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Novartis USD 47B 11.62B 2026-03
PTC Therapeutics USD 2.71B 2.42B 2025-12
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Thermo Fisher Scientific USD 39.39B 3.7B 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12